Association of a promoter variant of the haeme oxygenase-1 gene with @entity101 in XXXX .

@entity1 @entity101 @entity1223 @entity2931 @entity13975 @entity842 @entity1129
OBJECTIVE: To examine the relationship between the gene for @entity13975 ( @entity13975 ) and @entity1 essential @entity101 , because both the acute and systemic induction of @entity13975 have been suggested to attenuate vascular tone and blood pressure. METHODS: We screened for sequence variations in @entity13975 and conducted an association study, using these polymorphisms, in a large cohort (1998 individuals) representing the general Japanese population. RESULTS We sequenced @entity13975 and found a T(-413)A polymorphism in the promoter region. The frequency of @entity101 individuals and the use of antihypertensive drugs were significantly greater in the AA genotype than in other genotypes among @entity1 : 45.5, 34.2, and 35.0% (P = 0.0099) and 23.4, 17.5, and 15.0% (P = 0.038), respectively, for the AA, @entity1129 , and TT genotypes, respectively. However, this association was not observed in @entity1 . Multiple logistic analyses indicated that the T(-413)A (AA/TA+TT) polymorphism, age, and body mass index affected the occurrence of @entity101 in @entity1 . The odds ratio of the AA genotype for @entity101 in @entity1 was 1.59 (P = 0.0058; 95% confidence interval 1.14 to 2.20). A luciferase reporter assay indicated that the A allele-promoter had eight-fold greater activity than the T allele promoter (P < 0.01). CONCLUSIONS: The AA genotype of @entity13975 is associated with an increased incidence of @entity101 in @entity1 . @entity2931 attenuates vasoconstriction by increasing the expression of inducible @entity842 synthase. As @entity1223 , which is one of the products of @entity13975 , can attenuate @entity842 -induced vasodilatation, a high expression of @entity13975 may cause @entity101 , especially in @entity1 .
